Following an outbreak of carbapenem resistant Klebsiella pneumoniae (CRKP) bacteremia among inpatients in the Hemato-oncology and BMT unit, we studied the course of this infection in patients undergoing intensive chemotherapy and SCT. In addition, we conducted a pilot study aimed to eradicate CRKP colonization in the gastrointestinal tract, using oral gentamicin. Adult patients admitted to the BMT unit, identified as CRKP carriers on surveillance rectal cultures, were included in the study. Oral gentamicin at a dose of 80 mg q.i.d. was administered to all identified carriers until eradication. Among 15 colonized patients included in the study, the eradication rate achieved was 66% (10/15); discontinuation of persistent bacteremia occurred in 62.5% (5/8) and nosocomial spread of CRKP carrier state ceased. Administration of intensive chemotherapy and SCT is feasible, although associated with increased risk. Hematological patients in need of intensive chemotherapy/SCT should not be denied the required treatment on the basis of being CRKP carriers. Oral gentamicin treatment for eradication of CRKP from the gastrointestinal reservoir could serve as additional tool in the combat against the nosocomial spread and severe infections caused by this difficult-to-treat organism.
Introduction
Klebsiella pneumoniae, an inhabitant of the digestive tract, is a frequent nosocomial pathogen. It is currently the fourth most common cause of pneumonia and fifth most common cause of bacteremia in intensive care patients. 1 Liberal use of cephalosporins in the nineties caused the emergence of Enterobacteriaceae producing extended spectrum b lactamase and carbapenem resistance. 2 Several reports on hospital outbreaks of this highly resistant strain have been published. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] The New York area in the USA, as well as Israel and Greece, are considered as endemic regions for this infection. 13 Carbapenem resistant Klebsiella pneumoniae (CRKP) carrier state may be associated with the development of clinical disease in substantial number of patients with a mortality rate approaching 50%. 14, 15 Hematology patients receiving intensive leukemia type regimens and those undergoing SCT are particularly prone to CRKP infection due to a combination of contributing factors including prolonged neutropenia, protracted hospital stay in the intensive care unit setting (the BMT unit), frequent use of broad-spectrum antibiotics and mucositis, all of which contribute to the breakdown of normal body defense and occurrence of bacteremia with selected resistant bacteria. It has not yet been established whether patients who became chronic carriers of CRKP can be further treated, and particularly, if they can be offered intensive treatments, such as SCT.
Selective digestive gut decontamination, aimed to prevent secondary colonization through oral administration of non-absorbable antimicrobial agents, is used in intensive care units with conflicting results. 16, 17 A recent multicentercontrolled study from the the Netherlands demonstrated a decreased mortality rate using selective digestive gut decontamination. 18 In September 2008, the Hematology and BMT units at the Rambam Health Care Campus experienced an outbreak of CRKP colonization (carrier state), which continued despite strict hygiene and isolation measures. High incidence of persistent bacteremia was observed in patients even with the use of appropriate systemic antibiotic therapy. As these bacteria reside in the digestive tract and are sensitive to gentamycin, we decided to treat these patients with oral gentamicin with an aim to eradicate carrier state, prevent development of associated disease and control infection spread. This report describes the outcome of hematological patients, both carriers and infected with CRKP during leukemia-type intensive therapy and SCT, and the results of oral gentamicin administration.
Materials and methods
The Rambam Health Care Campus in Haifa, Israel, is a 900-bed tertiary-care teaching hospital, with a Hematooncology and BMT unit of 25 beds.
Between September 2008 and January 2009, adult patients admitted to Hematology-oncology and BMT department for intensive chemotherapy or hematopoietic SCT, who were identified as CRKP carriers on surveillance rectal swab cultures, were included in the study. The study was approved by the local ethics committee.
Surveillance rectal cultures were obtained from all inpatients thrice weekly, and once weekly after discharge. Blood and other relevant clinical cultures were taken as clinically indicated.
Colonization (carrier state) was defined as the presence of at least one rectal swab positive for CRKP. Eradication of colonization was confirmed if at least three consecutive rectal swabs obtained separately during a period of at least 7 days, were negative for CRKP. Persistent bacteremia was defined as positive blood cultures observed during at least 2 consecutive days.
Oral gentamicin at a dose of 80 mg q.i.d., was administered to all identified CRKP carriers until carrierstate eradication. High-risk patients, who subsequently underwent allogeneic HSCT, continued to receive oral gentamicin throughout the HSCT period despite apparent eradication.
Patients with CRKP-associated infection were additionally treated with i.v. gentamicin, colistin, tigecycline or a combination of the drugs. Blood levels of gentamicin were measured in all patients who did not receive i.v. gentamicin, to assure non-absorbance.
Microbiological studies
Cultures and identification of bacterial isolates were performed using conventional methods. Antimicrobial susceptibility was determined by disk diffusion according to the Clinical and Laboratory Standard Institute guidelines. 19 Susceptibility testing for imipenem, colistin and tigecycline was performed using E-test, according to the manufacturer's instructions (AB Biodisk, Solna, Sweden).
Rectal swab screening samples were plated directly on McConkey agar in the presence of ertapenem and imipenem antibiotic disks. DNA was extracted from suspected bacterial colonies using the Qiamp DNA mini kit (QIAgen, Hilden, Germany) in accordance with the manufacturer's instructions. CRKP was detected using PCR-based assays specific for K. pneumoniae hemolysin gene and blaKPC gene as previously described. 20 Data obtained for the study patients included: demographics, underlying diagnosis, type of treatment, neutropenia status and presence of central i.v. catheters. Duration and eradication of CRKP colonization was recorded, along with the duration of oral gentamicin treatment and gentamicin blood levels. Presence and duration of CRKP bacteremia or other CRKP infection were recorded, as well as concomitant anti-CRKP parenteral treatment. Survival status and CRKP infection-related mortality were determined.
Results
During a 5-month period, 15 patients identified as CRKP carriers, were included in the study. Median age of the cohort was 55 years (range: 32-80). Six patients underwent intensive chemotherapy for acute leukemia or relapsed lymphoma, one patient received immunosuppressive therapy for aplastic anemia and eight patients underwent SCT (six allogeneic and two autologous). Patient characteristics and outcome are presented in Table 1 .
Oral gentamicin was given to all patients for a median duration of 27 days (range: 7-90).
Gentamicin blood levels were measured in seven patients revealing the levels ranging between 0.0 and 0.4 mg/L.
A total of 219 rectal swabs were obtained from these 15 patients (range: 7-40 samples per patient), during a period of 20-150 days. Of these 219 rectal swabs, 104 were positive (1-19 per patient) and 115 were negative (0-26 per patient) for CRKP.
Eight patients (five during SCT and three during chemotherapy/immunosuppression) developed CRKP bacteremia, which lasted between 1-35 days (median duration of 8 days). Four of these patients had bacteremia as the only positive clinical isolate, and the other four had concomitant positive clinical isolates from respiratory secretions (two), urine (one) and i.v. catheter tip (one). Seven patients had severe neutropenia (ANC o100/mL) during bacteremia, and only one patient had a normal WBC count, but suffered from severe GVHD of the GI tract during bacteremia. All patients had a central i.v. catheter at time of bacteremia diagnosis. All CRKP clinical isolates were found to be susceptible to gentamicin, colistin and tigecycline, and resistant to all other tested antimicrobials. Patients with bacteremia were treated with i.v. combination of gentamicin þ tigecycline (one patient), or gentamicin þ colistin þ tigecycline (seven patients).
Following therapy bacteremia resolved in five out of eight patients, the other three patients died from persistent CRKP bacteremia. No gentamicin resistance was revealed in blood isolates during oral gentamicin treatment. GI tract colonization was eradicated in 10 of 15 carriers, and the eradication lasted for a median of 9 months (range: 2-10) of follow-up. Eradication was observed after 1-60 (median 27) days of oral treatment; in six patients the eradication became apparent in the first rectal swab obtained after initiation of oral treatment. Failure to achieve eradication was observed in five patients in whom colonization persisted for the entire period of oral treatment. All these five patients died, three of them because of CRKP bacteremia, and the other two of underlying disease. No significant side effects of the oral treatment were observed.
Discussion
This pilot study has demonstrated the feasibility of administering intensive leukemia-type chemotherapy and performing SCT in patients who were carriers of CRKP. To the best of our knowledge, this is the first report on the course of CRKP carrier and infection in this patient population. In addition, the study suggests an innovative approach using oral gentamycin for eradication of the carrier state and resolution of continuous bacteremia. In all, 66% of these high-risk patients managed to achieve eradication of the CRKP. In 5/8 (62.5%) bacteremic patients, CRKP eradication was accompanied by resolution of bacteremia. Formal statistical analysis was not performed because of the small number of patients in the study cohort.
Starting from 2007, about 20 new cases of CRKP infection and colonization were monthly diagnosed throughout our hospital wards, mainly in the general intensive care unit. 21 The decision to attempt the eradication of the GI carrier state came after observing several patients with persistent bacteremia, despite appropriate combination of parenteral antibiotic therapy and repeated changing of i.v. lines. Moreover, despite the implementation of strict contact isolation measures, as recently recommended by the Center for Disease Control, 22 newly colonized patients, identified by surveillance rectal cultures, emerged and new cases with CRKP bacteremia were registered.
Patel et al. 23 showed that treatment with antibiotics, to which the CRKP was susceptible in vitro, was not associated with an improved patient outcome, and removal of the focus of infection is currently the most effective means of improving survival. As the majority of patients undergoing intensive chemotherapy or HSCT suffer from severe mucositis, we speculated that CRKP, which resides in the GI tract, repeatedly invades the bloodstream through the damaged mucosa. Eradication of CRKP from the GI tract could possibly cause the removal of the 'focus of infection' and could thus lead to discontinuation of bacteremia. We also postulated that successful eradication of the carrier state would entail cessation of patient-topatient transmission and nosocomial spread of CRKP in the BMT unit.
Oral non-absorbable antibiotics have been used for many years as a means of selective decontamination of digestive tract, in order to reduce nosocomial infections in the intensive care unit setting. 18 Several attempts to control nosocomial outbreaks of infections with resistant organisms using gut decontamination were also reported. 24, 25 Oral gentamicin is a common component of the selective digestive tract decontamination regimen. Beginning with 2006, our hospital, as almost all major hospitals in Israel, observed continuous increase in clinical isolates of CRKP. 10, 12, 14, 21 At our hospital, strains were typed using pulse-field gel electrophoresis, and around 90% of them were found to be identical. 21 As the CRKP strain prevalent in our hospital setting is almost universally gentamicin susceptible 21 (as was the case in all the clinical isolates of our patients), and gentamicin is not absorbed from the GI tract, we chose this agent for oral treatment. Although the emergence of gentamicin resistance during prolonged treatment is of concern, this has not been identified in repeated clinical isolates in our patients.
Study-patient population received oral gentamicin for up to 90 days, without any significant side effects. Gentamicin blood levels showed minimal to none systemic absorption through the GI tract, despite significant mucositis. In addition, repeated CRKP clinical isolates did not show emergence of gentamicin resistance.
Natural history of CRKP carrier state is not precisely known, therefore no recommendations could be made by the Center for Disease Control 26 regarding the appropriate time point for discontinuation of contact precautions. Our governmental health authorities recommend continuing contact isolation for known CRKP carriers for 1 year after the last positive culture.
In this study, eradication of the carrier state was achieved in 10/15 of the patients, and was long lasting; in six of them eradication was apparent in the first culture after the beginning of oral treatment. Although in most patients the treatment was discontinued after three consecutive negative rectal swabs taken during a period of 7 days, high-risk patients, who subsequently underwent allogeneic HSCT, continued to receive oral gentamicin throughout the HSCT period despite apparent infection eradication.
Identified risk factors associated with acquisition of CRKP carrier state include previous use of fluoroquinolones and carbapenem drugs (odds ratio of 1.87 and 1.83, respectively), admission to an intensive care unit (odds ratio 4.27) and exposure to at least one antibiotic drug (odds ratio 3.93). 21 These risk factors are prevalent in hematological and, especially, SCT patients, which puts them at increased risk for contracting CRKP infection and for adverse outcome of this infection, as previously demonstrated. In a recent report describing the morbidity and mortality of patients with CRKP, the mortality risk ratio was 3.3 in patients with mostly non-malignant diseases. 27 In our study, 8/15 colonized patients developed bacteremia, and in all but one of them the bacteremia was persistent. In all, 7/8 of the bacteremic patients were neutropenic. In general, all the anti-microbial agents with in vitro antimicrobial activity against CRKP isolate (gentamicin, colistin and tigecycline) are considered suboptimal for the treatment of bacteremia during neutropenia 28 and are not associated with improved patient survival during the treatment of CRKP infection, in particular. 22 In the current study, 5/8 patients survived bacteremia, with the longest lasting 35 days. In addition, five patients acquiring CRKP colonization during intensive chemotherapy for acute leukemia, subsequently underwent successful allo-SCT while being maintained on oral gentamicin, without re-appearance of colonization or bacteremia. It is noteworthy that since the institution of oral gentamicin treatment for all CRKP carriers hospitalized in the hematology ward, no new carriers were identified in our patient population during the subsequent 6 months of follow-up.
The major limitation of our study is the lack of a control group. From this small cohort, the exact efficacy of the gentamicin oral treatment for improving survival of patients with CRKP infection cannot be determined. Similarly we cannot evaluate the exact efficacy of this intervention in respect to eradication of the CRKP carrier state, and cessation of nosocomial spread of this difficultto-treat organism. Another point that should be clearly stated is that this treatment approach is expected to be useful only for strains that are gentamicin susceptible, as our outbreak strain was; however, the efficacy of this approach could become very limited when dealing with a growing amount of other resistant clones with other carbapenemase genes. Nevertheless, this pilot study shows some promising results, specifically in this high-risk immunocompromised patient population, with a high rate of continuous bacteremia, despite appropriate treatment. These data are enough to prompt the conduct of a large scale, prospective randomized controlled trial, which is to be started at our medical center. This study will investigate natural history of the CRKP carrier state as well as the efficacy of different treatments for the infection eradication.
In summary, this is the first report of an outbreak of CRKP in hematological patients undergoing intensive chemotherapy and SCT. In addition, hematological patients in need for intensive chemotherapy/SCT should not be denied the required treatments on the basis of being CRKP carriers. Use of oral gentamicin for the eradication of the carrier state should further be studied.
